No image published for this recall

No image published for this recall

Ruzurgi Amifampridine 10 mg Tablet Bottle

Official notice

4 Oct 2021

Last checked

4 Oct 2021

Medium riskACCC

An official ACCC notice concerns Ruzurgi Amifampridine 10 mg Tablet Bottle. The effects of increased exposure to yeast and/or mould can include allergic reactions, asthma, neurotoxicity, sinusitis, otomycosis, onychomycosis, keratitis, respiratory infections, skin infections, and systemic infections. This may pose a serious health risk to users with weakened immune systems. Published 2021-10-04.

What to do now

Consumers who have been prescribed Ruzurgi Amifampridine 10 mg tablets, should check the batch number printed on the bottle. This recall does not affect any other batch of Ruzurgi, or any other ORSPEC Pharma products. Consumers will be contacted by a clinician to arrange for a replacement product. Anyone who is concerned about the use of this batch of product should consult their doctor. For more information, consumers can contact ORSPEC Pharma Customer Service on 02 4339 4239.

Recall number

8b2e0847-f8a3-41fb-a887-5d9ae96b1f67

Official notice

2021-10-04

The hazard

The effects of increased exposure to yeast and/or mould can include allergic reactions, asthma, neurotoxicity, sinusitis, otomycosis, onychomycosis, keratitis, respiratory infections, skin infections, and systemic infections. This may pose a serious health risk to users with weakened immune systems.

How to check if you're affected

Compare the product name and identifiers below with the item you own. Follow the official notice if they match.

Lots

18039, printed

Checked manually this time?

The app alerts you when a new official recall is published — no searching, no checking back.

Turn on recall alerts

Affected products

Product 1

Ruzurgi amifampridine 10 mg tablet bottle Batch Number: 18039 Exp: 3/2023 Supplied via Special Access Scheme (SAS)

Risk / hazard

The effects of increased exposure to yeast and/or mould can include allergic reactions, asthma, neurotoxicity, sinusitis, otomycosis, onychomycosis, keratitis, respiratory infections, skin infections, and systemic infections. This may pose a serious health risk to users with weakened immune systems.

Where it was sold

The source does not list specific retailers. See the official notice for where affected products were sold.

Location 1

AU · Australia

Affected area 1

AU · Australia

Source & status

Source

Tier

beta

Category

HOME

Classification

Pharmacy and medical products

App estimate

medium

Recall details

Recall number

8b2e0847-f8a3-41fb-a887-5d9ae96b1f67

Classification

Pharmacy and medical products

Source tier

beta

Documents, notices & source

See the official notice and source documents for full details.

View full official notice
Something wrong on this page?

Weekly recall digest

Get next week's recalls before you need them.

One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.

The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.

This recall was published 4 Oct 2021. The next one won't wait for you to search.

RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.